Literature DB >> 16904335

C-type natriuretic peptide and heart failure.

Silvia Del Ry1, Claudio Passino, Michele Emdin, Daniela Giannessi.   

Abstract

C-type natriuretic peptide (CNP) is a peptide produced by the vascular endothelium with vasodilative properties. It shares structural and physiological properties with the atrial and brain natriuretic peptides (ANP and BNP), whose central role in the pathophysiology of heart failure (CHF) is firmly established. The role of CNP, first isolated from porcine brain, has not been yet completely determined. The transcription of the gene, that in man is located on chromosome 2, is regulated by factors such as tumor necrosis factor and interleukin-1. Two mature forms of the peptide exist: CNP-53, that predominates in tissues and CNP-22, found mainly in plasma. As recently found, CNP is produced directly in the myocardium and an increase in plasma levels of this peptide and of its precursor was observed in CHF. The aim of this review was to examine the current literature relating to cardiovascular functions of CNP and in particular to its role in CHF. In fact, CNP may represent an important new local autocrine and endocrine mediator in CHF although further evaluations are required to define its full pathophysiological role in this disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16904335     DOI: 10.1016/j.phrs.2006.06.011

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  8 in total

1.  Canadian Cardiovascular Society Consensus Conference update on cardiac transplantation 2008: Executive Summary.

Authors:  H Haddad; D Isaac; J F Legare; P Pflugfelder; P Hendry; M Chan; B Cantin; N Giannetti; S Zieroth; M White; W Warnica; K Doucette; V Rao; A Dipchand; M Cantarovich; W Kostuk; R Cecere; E Charbonneau; H Ross; N Poirier
Journal:  Can J Cardiol       Date:  2009-04       Impact factor: 5.223

2.  Cardiac fibrosis in end-stage human heart failure and the cardiac natriuretic peptide guanylyl cyclase system: regulation and therapeutic implications.

Authors:  Tomoko Ichiki; John A Schirger; Brenda K Huntley; Frank V Brozovich; Joseph J Maleszewski; Sharon M Sandberg; S Jeson Sangaralingham; Soon J Park; John C Burnett
Journal:  J Mol Cell Cardiol       Date:  2014-08-09       Impact factor: 5.000

Review 3.  Novel vasodilators in heart failure.

Authors:  Payman Zamani; Barry H Greenberg
Journal:  Curr Heart Fail Rep       Date:  2013-03

Review 4.  Cardiac natriuretic peptides.

Authors:  Jens P Goetze; Benoit G Bruneau; Hugo R Ramos; Tsuneo Ogawa; Mercedes Kuroski de Bold; Adolfo J de Bold
Journal:  Nat Rev Cardiol       Date:  2020-05-22       Impact factor: 32.419

5.  The heart as an endocrine organ.

Authors:  Tsuneo Ogawa; Adolfo J de Bold
Journal:  Endocr Connect       Date:  2014-04-15       Impact factor: 3.335

6.  Regulation of Dopamine Uptake by Vasoactive Peptides in the Kidney.

Authors:  N L Rukavina Mikusic; N M Kouyoumdzian; E Rouvier; M M Gironacci; J E Toblli; B E Fernández; M R Choi
Journal:  Scientifica (Cairo)       Date:  2016-08-22

7.  Elevated N-terminal pro C-type natriuretic peptide is associated with mortality in patients undergoing transcatheter aortic valve replacement.

Authors:  Po Hu; Han Chen; Li-Han Wang; Ju-Bo Jiang; Jia-Min Li; Meng-Yao Tang; Yu-Chao Guo; Qi-Feng Zhu; Zhao-Xia Pu; Xin-Ping Lin; Stella Ng; Xian-Bao Liu; Jian-An Wang
Journal:  BMC Cardiovasc Disord       Date:  2022-04-12       Impact factor: 2.298

Review 8.  Natriuretic peptides and therapeutic applications.

Authors:  Candace Y W Lee; John C Burnett
Journal:  Heart Fail Rev       Date:  2007-06       Impact factor: 4.654

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.